Clovis Oncology, Inc.
(NASDAQ : CLVS)

( )
CLVS After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 1.74%306.720.0%$5163.15m
BNTXBioNTech SE 3.17%344.060.0%$1581.32m
NVAXNovavax, Inc. -0.92%160.4878.2%$849.64m
AMGNAmgen, Inc. 0.63%202.441.4%$596.99m
GILDGilead Sciences, Inc. -0.16%69.561.0%$508.98m
VRTXVertex Pharmaceuticals, Inc. -0.31%203.811.9%$477.50m
REGNRegeneron Pharmaceuticals, Inc. 0.18%635.162.7%$474.90m
LGVNLongeveron Inc. 11.78%20.120.0%$401.25m
ILMNIllumina, Inc. -2.85%347.283.3%$315.98m
SNSSSunesis Pharmaceuticals, Inc. -4.21%4.100.7%$286.61m
BIIBBiogen, Inc. -2.01%223.921.8%$273.37m
OCGNOcugen, Inc. -8.72%5.760.0%$193.29m
INCYIncyte Corp. -1.28%65.782.4%$154.23m
EXASEXACT Sciences Corp. -4.94%76.5918.0%$148.34m
SGENSeagen Inc. -5.00%150.745.8%$143.82m

Company Profile

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer; and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.